PanGen Biotech Inc. (KOSDAQ:222110)
South Korea
· Delayed Price · Currency is KRW 6,010.00
-190.00 (-3.06%)
At close: Apr 28, 2026
PanGen Biotech Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Operating Revenue | 13,417 | 14,673 | 7,315 | 6,501 | 7,936 | Upgrade
|
| Other Revenue | -0 | -0 | -0 | - | - | Upgrade
|
| Revenue | 13,417 | 14,673 | 7,315 | 6,501 | 7,936 | Upgrade
|
| Revenue Growth (YoY) | -8.56% | 100.58% | 12.53% | -18.08% | 28.18% | Upgrade
|
| Cost of Revenue | 8,919 | 9,534 | 6,343 | 5,858 | 7,420 | Upgrade
|
| Gross Profit | 4,498 | 5,139 | 971.8 | 642.47 | 515.69 | Upgrade
|
| Selling, General & Admin | 1,653 | 1,768 | 1,536 | 1,272 | 969.85 | Upgrade
|
| Research & Development | 1,382 | 2,012 | 3,332 | 3,850 | 2,734 | Upgrade
|
| Amortization of Goodwill & Intangibles | 124.89 | 124.06 | 111.88 | 46.82 | 40.05 | Upgrade
|
| Other Operating Expenses | 29.78 | 26.32 | 26.64 | 25.92 | 28 | Upgrade
|
| Operating Expenses | 2,991 | 4,118 | 5,197 | 5,233 | 3,804 | Upgrade
|
| Operating Income | 1,506 | 1,020 | -4,225 | -4,591 | -3,288 | Upgrade
|
| Interest Expense | -145.87 | -322.1 | -220.68 | -128.77 | -293.25 | Upgrade
|
| Interest & Investment Income | 424.43 | 184.78 | 41.75 | 246.57 | 179.7 | Upgrade
|
| Currency Exchange Gain (Loss) | -8.17 | 172.79 | 12.47 | 7.34 | 92.88 | Upgrade
|
| Other Non Operating Income (Expenses) | 273.52 | -91.83 | -64.6 | 37.97 | 59.88 | Upgrade
|
| EBT Excluding Unusual Items | 2,050 | 963.8 | -4,457 | -4,428 | -3,249 | Upgrade
|
| Gain (Loss) on Sale of Assets | 17.01 | 13.94 | 15.15 | -0.24 | -0.67 | Upgrade
|
| Other Unusual Items | - | 25.85 | - | -7.39 | - | Upgrade
|
| Pretax Income | 2,067 | 1,004 | -4,441 | -4,435 | -3,250 | Upgrade
|
| Income Tax Expense | 16.53 | 59.9 | 47.43 | 58.69 | 60.5 | Upgrade
|
| Net Income | 2,051 | 943.69 | -4,489 | -4,494 | -3,310 | Upgrade
|
| Net Income to Common | 2,051 | 943.69 | -4,489 | -4,494 | -3,310 | Upgrade
|
| Net Income Growth | 117.30% | - | - | - | - | Upgrade
|
| Shares Outstanding (Basic) | 13 | 12 | 11 | 11 | 10 | Upgrade
|
| Shares Outstanding (Diluted) | 14 | 12 | 11 | 11 | 10 | Upgrade
|
| Shares Change (YoY) | 22.05% | 7.78% | 0.03% | 4.47% | 6.02% | Upgrade
|
| EPS (Basic) | 154.00 | 82.00 | -420.40 | -421.00 | -324.00 | Upgrade
|
| EPS (Diluted) | 146.00 | 82.00 | -420.40 | -421.00 | -324.00 | Upgrade
|
| EPS Growth | 78.05% | - | - | - | - | Upgrade
|
| Free Cash Flow | -373 | 2,627 | -3,873 | -4,231 | -4,749 | Upgrade
|
| Free Cash Flow Per Share | -26.56 | 228.26 | -362.70 | -396.34 | -464.83 | Upgrade
|
| Gross Margin | 33.52% | 35.02% | 13.29% | 9.88% | 6.50% | Upgrade
|
| Operating Margin | 11.23% | 6.95% | -57.76% | -70.62% | -41.44% | Upgrade
|
| Profit Margin | 15.28% | 6.43% | -61.36% | -69.13% | -41.72% | Upgrade
|
| Free Cash Flow Margin | -2.78% | 17.90% | -52.94% | -65.08% | -59.85% | Upgrade
|
| EBITDA | 2,972 | 2,489 | -2,629 | -2,987 | -1,756 | Upgrade
|
| EBITDA Margin | 22.15% | 16.96% | -35.94% | -45.96% | -22.13% | Upgrade
|
| D&A For EBITDA | 1,465 | 1,468 | 1,597 | 1,603 | 1,532 | Upgrade
|
| EBIT | 1,506 | 1,020 | -4,225 | -4,591 | -3,288 | Upgrade
|
| EBIT Margin | 11.23% | 6.95% | -57.76% | -70.62% | -41.44% | Upgrade
|
| Effective Tax Rate | 0.80% | 5.97% | - | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.